How are life sciences organizations creating value from real-world data?

Senior leaders from Novo Nordisk, Bayer, Johnson & Johnson, and Takeda discuss how to move RWD from a supporting resource to a genuine strategic asset.

Read here

From claims to commercial strategy: Finding actionable insights in rare disease data

Deep Dive from the World Orphan Drug Congress USA 2026.

Read here

Can we trust AI-generated RWD? A systematic validation approach in prostate cancer

Eunice Hankinson (Flatiron Health) discusses use of the VALID Framework to evaluate an LLM-extracted prostate cancer dataset.

Read here

How the Premier Healthcare Database supports real-world evidence

Insights from research presented at ISPOR 2026.

Read here

WEBINAR: An HEOR playbook for oncology RWE and AI use to support European HTA

How oncology RWD and AI-enabled evidence generation can strengthen EU HTA submissions under JCA.

Innovation without access? The growing tension in rare disease coverage

Discussions from the World Orphan Drug Congress USA 2026.

Read here

HOME
NEWS
FEATURES
TOPICS
EVENTS
ABOUT
SPONSORSHIP

Share on

Facebook
X
LinkedIn
Reddit
Bluesky

News

28 Jul 2026

Another JCA initiated as daraxonrasib enters EU HTA process alongside EMA phased review
27 Jul 2026

Critical Path Institute expands rare disease data platform through Across Healthcare partnership

Deep Dives

21 Jul 2026

From claims to commercial strategy: Finding actionable insights in rare disease data
15 Jul 2026

Following the patient journey: How connected data and evolving methods are reshaping real-world evidence

WEBINARS

18 Jun 2026

WEBINAR: An HEOR playbook for oncology RWE and AI use to support European HTA – VIEW ON DEMAND
9 Apr 2026

WEBINAR: Connecting the dots: Overcoming data and RWE challenges – VIEW ON DEMAND

EXPERT INSIGHTS

22 Jul 2026

Can we trust AI-generated RWD? A systematic validation approach in prostate cancer
10 Jul 2026

How the Premier Healthcare Database supports real-world evidence: Insights from research presented at ISPOR 2026

Interested in learning more about our sponsorship opportunities?

Click here

SPOTLIGHTS

Most-Favored-Nation

15 Jul 2026

Market access and HTA developments with Sreeram Ramagopalan: The HEMA benefits debate and delays in health plan coverage updates
14 Jul 2026

Hot off the press: Part two of our pick of articles within HTA and RWE published in June 2026
6 Jul 2026

CMS launches Medicare GLP-1 Bridge to inform future obesity drug coverage

JCA in Europe

28 Jul 2026

Another JCA initiated as daraxonrasib enters EU HTA process alongside EMA phased review
21 Jul 2026

HTA Coordination Group issues guidance on AI use in Joint Clinical Assessment dossier preparation
21 Jul 2026

Building readiness for HTA through horizon scanning and real-world evidence: Insights from the RWE4Decisions webinar

ISPOR 2026

22 Jul 2026

Can we trust AI-generated RWD? A systematic validation approach in prostate cancer
15 Jul 2026

Following the patient journey: How connected data and evolving methods are reshaping real-world evidence
10 Jul 2026

How the Premier Healthcare Database supports real-world evidence: Insights from research presented at ISPOR 2026

Interested in the Journal of Comparative Effectiveness Research?

Click here

FEATURED TOPICS

Health Economics

15 Jul 2026

Following the patient journey: How connected data and evolving methods are reshaping real-world evidence
15 Jul 2026

ISPOR Special Task Force introduces IMPACT framework for value-based healthcare implementation
14 Jul 2026

Hot off the press: Part two of our pick of articles within HTA and RWE published in June 2026

Health Technology Assessment

28 Jul 2026

Another JCA initiated as daraxonrasib enters EU HTA process alongside EMA phased review
24 Jul 2026

ISPOR white paper recommends coordinated evidence generation across European healthcare decision-making
24 Jul 2026

Flatiron Health brings Scottish oncology data into global real-world evidence network

Real-World Evidence

27 Jul 2026

Critical Path Institute expands rare disease data platform through Across Healthcare partnership
24 Jul 2026

ISPOR white paper recommends coordinated evidence generation across European healthcare decision-making
24 Jul 2026

Flatiron Health brings Scottish oncology data into global real-world evidence network

Market Access

24 Jul 2026

Flatiron Health brings Scottish oncology data into global real-world evidence network
21 Jul 2026

Building readiness for HTA through horizon scanning and real-world evidence: Insights from the RWE4Decisions webinar
20 Jul 2026

Ireland’s NCPE applies EU Joint Clinical Assessment in first national HTA review

How are life sciences organizations creating value from real-world data?

From claims to commercial strategy: Finding actionable insights in rare disease data

Can we trust AI-generated RWD? A systematic validation approach in prostate cancer

How the Premier Healthcare Database supports real-world evidence

WEBINAR: An HEOR playbook for oncology RWE and AI use to support European HTA

Innovation without access? The growing tension in rare disease coverage

News

Another JCA initiated as daraxonrasib enters EU HTA process alongside EMA phased review

Critical Path Institute expands rare disease data platform through Across Healthcare partnership

Deep Dives

From claims to commercial strategy: Finding actionable insights in rare disease data

Following the patient journey: How connected data and evolving methods are reshaping real-world evidence

WEBINARS

WEBINAR: An HEOR playbook for oncology RWE and AI use to support European HTA – VIEW ON DEMAND

WEBINAR: Connecting the dots: Overcoming data and RWE challenges – VIEW ON DEMAND

EXPERT INSIGHTS

Can we trust AI-generated RWD? A systematic validation approach in prostate cancer

How the Premier Healthcare Database supports real-world evidence: Insights from research presented at ISPOR 2026

SPOTLIGHTS

Market access and HTA developments with Sreeram Ramagopalan: The HEMA benefits debate and delays in health plan coverage updates

Hot off the press: Part two of our pick of articles within HTA and RWE published in June 2026

CMS launches Medicare GLP-1 Bridge to inform future obesity drug coverage

Another JCA initiated as daraxonrasib enters EU HTA process alongside EMA phased review

HTA Coordination Group issues guidance on AI use in Joint Clinical Assessment dossier preparation

Building readiness for HTA through horizon scanning and real-world evidence: Insights from the RWE4Decisions webinar

Can we trust AI-generated RWD? A systematic validation approach in prostate cancer

Following the patient journey: How connected data and evolving methods are reshaping real-world evidence

How the Premier Healthcare Database supports real-world evidence: Insights from research presented at ISPOR 2026

Following the patient journey: How connected data and evolving methods are reshaping real-world evidence

ISPOR Special Task Force introduces IMPACT framework for value-based healthcare implementation

Hot off the press: Part two of our pick of articles within HTA and RWE published in June 2026

Another JCA initiated as daraxonrasib enters EU HTA process alongside EMA phased review

ISPOR white paper recommends coordinated evidence generation across European healthcare decision-making

Flatiron Health brings Scottish oncology data into global real-world evidence network

Critical Path Institute expands rare disease data platform through Across Healthcare partnership

ISPOR white paper recommends coordinated evidence generation across European healthcare decision-making

Flatiron Health brings Scottish oncology data into global real-world evidence network

Flatiron Health brings Scottish oncology data into global real-world evidence network

Building readiness for HTA through horizon scanning and real-world evidence: Insights from the RWE4Decisions webinar

Ireland’s NCPE applies EU Joint Clinical Assessment in first national HTA review